Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Visual outcomes and patient satisfaction following implantation of two trifocal intraocular lenses with different intermediate focal distances

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Multifocal IOLs

Venue: Poster Village: Pod 1

First Author: : M.Holzer GERMANY

Co Author(s): :    T. Rabsilber   G. Auffarth   B. Thomas        

Abstract Details

Purpose:

To evaluate functional outcomes of two trifocal intraocular lenses (IOL) with different intermediate focal distances: the AcrySof IQ PanOptix (Alcon Inc.) and AT Lisa tri 839 MP (Carl Zeiss Meditec AG).

Setting:

Prospective, single-center study. University of Heidelberg, Department of Ophthalmology, Heidelberg, Germany.

Methods:

Cataract and refractive lens exchange patients with implantation of PanOptix or AT Lisa tri & tri toric were examined 3 months postoperatively. Refraction, uncorrected/corrected distance (UDVA/CDVA), uncorrected/distance-corrected intermediate (60 or 80 cm, UIVA/DCIVA), uncorrected/distance corrected/corrected near visual acuities (40 cm, UNVA, DCNVA, CNVA), defocus curves and subjective questionnaire were performed.

Results:

26 eyes of 13 patients (PanOptix) and 27 eyes of 14 patients (AT Lisa tri/AT Lisa tri toric) were examined. Median monocular visual acuities (PanOptix/AT Lisa tri & tri toric) were: UDVA 0.02/0.02 logMAR, CDVA -0.04/-0.04 logMAR, UIVA (60/80 cm) 0.04/0.06 logMAR, DCIVA (60/80 cm) 0.04/0.02 logMAR, UNVA 0.04/0.10 logMAR and DCNVA 0.02/0.08 logMAR. The PanOptix had a median deviation from target refraction of 0.02 D (range -0.59 to 0.53 D) and the AT Lisa tri & tri toric of 0.35 D (range -0.48 to 1.22 D) (p=0.0007). Patient satisfaction was comparable.

Conclusions:

Both trifocal IOLs revealed good results for distance, intermediate and near visual acuity with differences in the defocus curves. The PanOptix had a slightly better outcome regarding achievement of target refraction.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company

Back to previous